Atritech
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Total Raised
$91.82MInvestors Count
12Deal Terms
5Atritech Funding, Atritech Valuation & Atritech Revenue
7 Fundings
Atritech's latest funding round was a Unattributed for $30M on March 13, 2009.
Atritech's valuation in September 2007 was $96.45M.
Atritech's latest post-money valuation is from March 2009.
Sign up for a free trial to see Atritech's valuations in March 2009, March 2006 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
3/13/2009 | Unattributed | $30M | ||||
9/7/2007 | Series D | ▲$96.45M | ||||
3/13/2006 | Series C | |||||
10/17/2003 | Series B | |||||
4/1/2001 | Unattributed - II |
Date | 3/13/2009 | 9/7/2007 | 3/13/2006 | 10/17/2003 | 4/1/2001 |
|---|---|---|---|---|---|
Round | Unattributed | Series D | Series C | Series B | Unattributed - II |
Amount | $30M | ||||
Investors | |||||
Valuation | ▲$96.45M | ||||
Revenue | |||||
Sources |
Atritech Deal Terms
5 Deal Terms
Atritech's deal structure is available for 5 funding rounds, including their Unattributed from March 13, 2009.
Round | Unattributed | Series D | Series C | Series B | Series A |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unattributed | |||||||||||||||
Series D | |||||||||||||||
Series C | |||||||||||||||
Series B | |||||||||||||||
Series A |
Atritech Investors
12 Investors
Atritech has 12 investors. Affinity Capital Management invested in Atritech's Series D funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/17/2003 | 3/13/2009 | 4 Unattributed, Series B (2003), Series C (2006), Series D (2007) | Venture Capital | Minnesota | ||
3/13/2006 | 3/13/2009 | 4 Unattributed, Other Investors (0), Series C (2006), Series D (2007) | Private Equity | Connecticut | ||
3/13/2006 | 3/13/2009 | 3 Unattributed, Series C (2006), Series D (2007) | Venture Capital | Massachusetts | ||
Venture Capital | Minnesota | |||||
Private Equity | California |
First funding | 10/17/2003 | 3/13/2006 | 3/13/2006 | ||
|---|---|---|---|---|---|
Last Funding | 3/13/2009 | 3/13/2009 | 3/13/2009 | ||
Investor | |||||
Rounds | 4 Unattributed, Series B (2003), Series C (2006), Series D (2007) | 4 Unattributed, Other Investors (0), Series C (2006), Series D (2007) | 3 Unattributed, Series C (2006), Series D (2007) | ||
Board Seats | |||||
Type | Venture Capital | Private Equity | Venture Capital | Venture Capital | Private Equity |
Location | Minnesota | Connecticut | Massachusetts | Minnesota | California |
You May Also Like
MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.
Windy Hill Medical is a medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration
CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.
Salutaris Medical Devices (SalutarisMD) is a clinical-stage medical device company developing an investigational ophthalmic treatment for Wet Age-related Macular Degeneration (Wet AMD). SalutarisMD is developing a minimally invasive procedure that can be performed in an outpatient or physician office setting in approximately 15 minutes.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.